Financials in USD. Standardized financial statements.
A compact view of how Applied Biosciences Corp. turns revenue into operating income and net income.
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $88,665 | $723,351 | $707,062 | $197,554 | $45,554 | $0 | $0 | $0 |
| Revenue Growth? | -87.7% | +2.3% | +257.9% | +333.7% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $406,549 | $436,554 | $521,774 | $155,549 | $6,391 | $0 | $0 | $0 |
| Gross Profit? | -$317,884 | $286,797 | $185,288 | $42,005 | $39,163 | $0 | $0 | $0 |
| Gross Margin? | -358.5% | +39.6% | +26.2% | +21.3% | +86.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $374,872 | $3.38M | $2.83M | $1.54M | $178,717 | $28,445 | $16,669 | $1,822 |
| Operating Income? | -$692,756 | -$3.09M | -$2.65M | -$599,530 | -$515,920 | -$28,445 | -$16,669 | -$1,822 |
| EBITDA? | -$725,175 | -$3.75M | -$1.99M | -$2.16M | -$119,598 | $0 | -$16,669 | -$1,822 |
| Income Before Tax | -$899,668 | -$4.97M | -$2.68M | -$2.39M | -$515,920 | -$28,445 | -$16,669 | -$1,822 |
| Income Tax Expense | $0 | $0 | $0 | $882,904 | $378,102 | -$98,112 | $0 | $0 |
| Net Income? | -$767,220 | -$4.67M | -$2.63M | -$2.38M | -$517,656 | -$28,445 | -$16,669 | -$1,822 |
| EPS? | $-0.04 | $-0.34 | $-0.22 | $-0.16 | $-0.04 | $-0.00 | $-0.00 | $-0.00 |
| Diluted EPS? | $-0.06 | $-0.34 | $-0.22 | $-0.16 | $-0.04 | $-0.00 | $-0.00 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality